Skip to main content

Table 2 Mutual exclusivity and co-occurrence of the top 50 mutated genes in BLCA

From: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

A B Neither A not B B not A Both Log2 odds ratio p value q value Tendency
TP53 FGFR3 169 185 45 13 − 1.922 < 0.001 0.003 Mutual exclusivity
RB1 FGFR3 284 70 56 2 − 2.787 < 0.001 0.02 Mutual exclusivity
TP53 RB1 199 141 15 57 2.423 < 0.001 < 0.001 Co-occurrence
RYR1 AHNAK 337 33 25 17 2.796 < 0.001 < 0.001 Co-occurrence
BIRC6 ADGRV1 333 34 28 17 2.572 < 0.001 0.001 Co-occurrence
SYNE1 AHNAK 307 63 21 21 2.285 < 0.001 0.002 Co-occurrence
FGFR3 STAG2 317 38 37 20 2.173 < 0.001 0.002 Co-occurrence
KDM6A STAG2 277 78 28 29 1.879 < 0.001 0.002 Co-occurrence
MUC16 BIRC6 272 89 23 28 1.896 < 0.001 0.003 Co-occurrence
TTN MUC16 174 121 43 74 1.307 < 0.001 0.005 Co-occurrence